Mark Klein
Pulmonary Disease · Salinas, CANPI 1093718165
Payments from drug & device makers
Across 288 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$450
- Actelion Pharmaceuticals US, Inc.$436
- Boehringer Ingelheim$430
- Grifols USA, LLC$341
- AbbVie$304
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,79098%
- Education$1072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 130 | $2,777 |
| AstraZeneca | 29 | $450 |
| Actelion Pharmaceuticals US, Inc. | 20 | $436 |
| Boehringer Ingelheim | 24 | $430 |
| Grifols USA, LLC | 16 | $341 |
| AbbVie(2 entities) | 11 | $304 |
| Sanofi | 13 | $267 |
| Amgen | 8 | $182 |
| Novartis | 8 | $158 |
| Teva Pharmaceuticals USA, Inc. | 6 | $119 |
| Electromed, Inc. | 5 | $68 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Sunovion Pharmaceuticals Inc. | 3 | $49 |
| Philips North America LLC | 3 | $46 |
| Merck | 2 | $39 |
| Gilead | 2 | $39 |
| Bayer | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,897 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $26,403 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $11,948 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,798 |
| Roflumilast | 17 | $2,045 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,733 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $1,084 |
| Montelukast Sodium | 39 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,777 | $50,14879 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Salinas
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.